Just saw that Arcutis dropped some solid phase 2 results for ZORYVE cream in infants with atopic dermatitis. They tested it on 101 babies aged 3-23 months and got 58% hitting that EASI-75 improvement mark at week 4. That's actually pretty decent for such a young population. Safety profile looked clean too, no new issues popping up. The cream already got FDA green light last year for kids 2-5 with dermatitis, so extending it to even younger infants makes sense if the data holds. They're planning to file the supplemental application next quarter to push for that expanded indication. Interesting move in the pediatric space - treating dermatitis in babies is no joke for parents. Stock was at $25.37 late January but curious where it settles with this news. Biotech clinical wins like this don't always move the needle though. What's your take on the safety profile for such young kids?